– SWEDEN, Stockholm – Palette Life Sciences, a fully integrated global life sciences company dedicated to improving patient outcomes, today announced the expansion of its Board of Directors by adding five new members:
- Dave Amerson (Chairman)
- Newton Aguiar
- Dr. Ted Lamson
- Gun Nilsson
- Paul De Potocki
“We are excited to strengthen our team with the appointment of exceptional leaders. Each will provide significant expertise in their respective functions as we expand our product portfolio and deliver best in class care to our patients worldwide.” said CEO, Per Langö.
The company also announced the completion during the spring of a $30 million equity financing led by the investment firm Melker Schörling AB and a global player in the Oncology space.
Per Langö added: “This capital raise allows Palette Life Sciences to continue to expand our commercial presence in the United States and other key markets and bring products like Barrigel to the global marketplace.”
With the addition of the new members, the Board of Directors now consists of eight members bringing vast operational expertise to the company through their advisory roles. The new board members join current Directors, Per Langö (CEO), Mattias Klintemar, and Paul De Potocki.
About Dave R. Amerson
Dave Amerson (Chairman) is a former CEO of NeoTract and former president of the Teleflex Urology franchise. He currently serves as Chairman of NC8, an ExploraMed company. Mr. Amerson also serves as a board member of Calyxo Medical. In addition, he was global VP and GM of Coloplast’s Surgical Urology Division and global VP of sales and marketing for Mentor’s urology division.
About Newton Aguiar
Newton Aguiar, an independent investor, and advisor is a former managing director at Credit Suisse London office. Previous roles include senior health care advisor at Warburg Pincus LLC and a partner at Avista Capital Partners. Mr. Aguiar has been involved with several successful health care investments and in addition to Palette Life Sciences, he currently sits on the board of OssDsign AB.
About Dr. Ted Lamson
Dr. Ted Lamson (Ph.D.) is co-founder of NeoTract and co-inventor of UroLift for enlarged prostates. He served as CTO for Clinical and Medical Affairs in Teleflex. He is a Strategic Advisor to ExploraMed and serves on the board of Eximis Surgical and advisor to Calyxo. Dr. Lamson has also held management roles in Medtronic and Pfizer.
About Sam Navarro
Sam Navarro is the managing partner and founder of Gravitas Healthcare LLC. Among his previous roles, he was senior portfolio manager of the Galleon Group Healthcare Fund and Global Head of Healthcare Investment Banking at ING Barings. Mr. Navarro is also on the Board of Directors of BioSig Technologies.
About Gun Nilsson
Gun Nilsson is CEO of Melker Schorling AB, and former CEO of Gambro Holding AB. Ms. Nilsson also serves as Chairman of the Board of Hexagon AB, and a member of the boards of AAK, Absolent, Hexpol, Bonnier Group AG, Loomis AB and Einar Mattsson. Ms. Nilsson is also Chairman of the Swedish Corporate Governance Board and has vast operational experience from several public companies.
About Palette Life Sciences
Palette Life Sciences is a fully integrated life sciences company. Palette Life Sciences’ products improve patient outcomes in urology and urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. The company’s portfolio of available products includes Deflux, Barrigel, Solesta, and Lidbree. Palette Life Sciences moves rapidly to leverage novel applications of existing technologies to create breakthrough medical solutions. This focus enables the company to serve those often overlooked by traditional medical companies and improve patient quality of life. Led by experienced healthcare executives, Palette Life Sciences is headquartered in Stockholm, Sweden, with offices in Santa Barbara, California, Dallas, Texas, and Sydney, Australia.
For more information: https://www.palettelifesciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
